← All trials
NCT04476069
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2019
- Primary completion
- Mar 28, 2019
- Completion date
- May 30, 2019
- First posted
- Jul 17, 2020
- Last posted
- Jul 17, 2020
- Enrollment
- 56
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Princess Nourah Bint Abdulrahman UniversityLead sponsor
- Princess Nourah Bint Abdulrahman UniversityReponsible party - principal investigator
- Princess Nourah Bint Abdulrahman UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.